- New
Reference: BAC10
Reference: 3MLTFRSYRINGE
Reference: BAC3
Reference: RETADPEN10
Reference: v3penblk
Tirzepatide was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.
For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, and must not be misused in any way that contravenes MHRA regulations or applicable laws.
Tirzepatide was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.
Unlike its predecessor Semaglutide (which only targets GLP-1), Tirzepatide showed 5–7% more weight loss in clinical trials. Compared to Retatrutide, a triple agonist, Tirzepatide accomplished nearly the same weight loss but over a longer period (72 weeks vs. 48).
Mechanism of Action
Benefits
Possible Side Effects (often mild and temporary; affected only ~25% in trials)
Rare but serious risks
Contraindications
=================================================================================================
Stacking Suggestions
Your review appreciation cannot be sent
Report comment
Report sent
Your report cannot be sent
Write your review
Review sent
Your review cannot be sent
Reference: ADAMDP10
Reference: KLOWDPEN80
Reference: PT141DP10
Reference: GHKCUDPEN50
Reference: RETADPEN10
Reference: SELDP10
Reference: MT2DP10
Reference: ADIPDP10
Reference: CJCIPADPEN10
Reference: KPVDP10
Reference: MT1DP10
Reference: BPCTBDPEN10
Reference: DSIPDP5
Reference: MOTSCDPEN10
Reference: BPC157DPEN10
Reference: CAGDPEN5
Tirzepatide was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.
For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, and must not be misused in any way that contravenes MHRA regulations or applicable laws.
check_circle
check_circle